Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BERGEN BRUNSWIG DRUG AND HEALTH CARE SALES UP 16% TO NEARLY $1 BIL. IN THIRD QUARTER; BIOCRAFT FY 1990 SALES INCREASE 27% TO TOP $100 MIL. MARK

Executive Summary

Bergen Brunswig revenues from its prescription drug and health care products distribution business climbed 16.2% to $997.5 mil. in the third quarter ended May 31. Through nine months of fiscal 1990, drug and health care sales have risen 15.2% to $2.9 bil. Consolidated revenues for the third quarter and nine months rose 15.7% and 13.4%, respectively, to $1.14 bil. and $3.3 bil. Quarterly drug distribution operating profits rose 14.5% to $33 mil.; in the year so far, profits from that business are ahead 13.5% at $86.4 mil. Corporate net earnings also jumped significantly -- quarterly earnings were $21.3 mil., up 58%, and net income through nine months is $51.5 mil., up nearly 40%. * Biocraft Labs fourth quarter sales slipped 2% to $28 mil. for the three months ending March 31. Fiscal 1990 revenues increased 26.9% to $113.6 mil. President and CEO Harold Snyder, reporting financial results on June 6, said sales of Biocraft's antibiotics "continued strong." Commenting on earnings for the quarter and the year, Snyder noted: "Obviously, the results of fiscal 1990 were distorted by the settlement of the cefadroxil litigation." At the end of March, Biocraft and Zenith Labs agreed to pay cefadroxil patent holder Bristol-Myers Squibb and to halt sales of their generic versions of the antibiotic Duricef. Biocraft agreed to pay $10 mil. to Bristol in FY 1991 and additional payments over seven years. Bristol said the total was$21 mil. ("The Pink Sheet" April 2, T&G-12). The one-time charge to earnings showed up in the fourth quarter as a $7.9 mil. net loss. For the year, Biocraft earnings were $3.2 mil., a 61.5% plunge from FY 1989.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS017602

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel